Hadassah

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Wednesday, Jan 10 2018

Illustration of the positive impact of Namodenoson, as compared to treatment of animals with a placebo (“vehicle”)

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

The new drug called Namodenoson, Dr. Safadi says, “is unique among today’s NASH drugs under development due to its excellent safety profile and the positive effect on steatosis (accumulation of fat in the liver), inflammation, and fibrosis (liver scarring, which results from dying of liver cells, also referred to as ballooning).”  Improvement in these parameters translates into a significant anti-NASH effect.

Namodenoson has been granted Orphan Drug Designation in the United States and Europe and Fast Track Designation as a second-line treatment for hepatocellular cancer by the United States Food and Drug Administration. It has the potential to be effective in treating other cancers, including colon and prostate cancer, as well as melanoma.

Can-Fite has initiated enrollment for a Phase II study with Namodenoson in NASH and NAFLD (non-alcoholic fatty liver disease) patients who show evidence of active inflammation. The focus will be on measuring the drug’s anti-inflammatory effect and its success in reducing fat in the liver.

A prolific researcher, renowned for his work with NASH, Dr. Safadi is also a member of Can-Fite’s Clinical Advisory Board. “We are privileged to work with Dr. Safadi to further study and advance the drug’s mechanism of action,” notes Pnina Fishman, PhD, Founder and Chief Executive Officer of Can-Fite.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jan 11 2018

Hadassah’s Heart Institute: Innovation at the Forefront

Prof. Chaim Lotan, head of the Hadassah Medical Organization’s Heart Institute, has made it a personal objective to foster innovation in cardiovascular technology.

READ MORE ›
alt_text

Thursday, Jan 11 2018

Medical Clown Nehama’s Blog, Chapter Five: Out of Love

“I met Masha in the surgery waiting room at Hadassah Hospital Ein Kerem,” says Medical Clown Shira, as she proceeds to convey this story: Masha is a three-year-old girl who lives in Russia. Every three months, she comes to Hadassah for an oncological examination under full anesthesia.

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Bedridden Teen Walks Again, Thanks to First-in-Israel Complex Spinal Surgery at Hadassah

Yusef Rabaya, age 19, spent most of his life in bed at home in Jenin. Born with cerebral palsy (CP), he could sit only if he was propped up. Standing was excruciating and dangerous--and could cause permanent paralysis.

READ MORE ›
alt_text

Wednesday, Dec 27 2017

Head of Hadassah’s R & D Invited to Thailand for Royal Celebration and Conference

Prof. Eyal Mishani, head of Research and Development at the Hadassah Medical Organization and a professor of radiology and molecular imaging, was invited to present at the academic medical conference in Bangkok, Thailand, as part of a 60th birthday celebration for Princess Chulabhorn Walailak, a professor of biochemistry.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More